Samit Shah serves as the President and Chief Executive Officer of Kymera Therapeutics, leading the clinical-stage biopharmaceutical enterprise through its strategic evolution in targeted protein degradation discovery. Under his executive direction, the company continues to advance its proprietary Pegasus platform, manage key pharmaceutical partnership agreements, and guide its pipeline of novel small-molecule therapeutics through rigorous clinical evaluations designed to address severe immunological diseases and complex oncology conditions.